The COVID-19 pandemic has been occurring approximately for more than 1 year. This pandemic has been a health issue that hits all countries in the world caused by the transmission of SARS-CoV-2 virus from one individual to another. The symptoms showed from the infected are fever, shortness of breath, dry cough, headache, and sore throat, among others. The SARS-CoV-2 virus is transmitted through sneezing, coughing, talking, and touching infected objects. Along with this transmission, the SARS-CoV-2 virus will continue to mutate. This mutation becomes an obstacle as well as a challenge to find drugs that can overcome the SARS-CoV-2 virus effectively and safely. The drugs used as anti-COVID-19 are still limited. The steps taken in the process of discovering and developing anti-COVID-19 drugs were through the drug repurposing approach because of the advantages it provides, such as shortens the duration and minimizes the costs required. After several drugs that have potential as anti-COVID-19 were obtained, further research on the development of dosage forms and formulas was carried out to obtain more effective and safer anti-COVID-19 drugs. This review aims to discuss several drugs gained from drug repurposing that have the potential as anti-COVID-19 drugs such as remdesivir, chloroquine/hydroxychloroquine, azithromycin, corticosteroids, and other potential drugs. This review will also discuss several developments of dosage form from the repurposed drugs.


Agrawal, P. (2015). Advantages and Challenges in Drug Re-Profiling. Journal of Pharmacovigilance, s2, 2–3. https://doi.org/10.4172/2329-6887.s2-e002

Ahmed, M. H., & Hassan, A. (2020). Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review. SN comprehensive clinical medicine, 1-10.

Behrens, E. M., & Koretzky, G. A. (2017). Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era. Arthritis and Rheumatology, 69(6), 1135–1143. https://doi.org/10.1002/art.40071

Cao, J., Forrest, J. C., & Zhang, X. (2015). A screen of the NIH clinical collection smal molecule library identifies potential anti-coronavirus drugs. Antiviral research, 114(2015), 1-10. https://dx.doi.org/10.1016/j.antiviral.2014.11.010

Cavalcanti, I. D. L., & Cajubá de Britto Lira Nogueira, M. (2020). Pharmaceutical nanotechnology: which products are been designed against COVID-19? Journal of Nanoparticle Research, 22(9). https://doi.org/10.1007/s11051-020-05010-6

Channappanavar, R., & Perlman, S. (2017). Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Seminars in Immunopathology, 39(5), 529–539. https://doi.org/10.1007/s00281-017-0629-x

Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., Zhang, X., Zhang, M., Wu, S., Song, J., Chen, T., Han, M., Li, S., Luo, X., Zhao, J., & Ning, Q. (2020). Clinical and immunological features of severe and moderate coronavirus disease 2019. The Journal of clinical investigation, 130(5), 2620-2629.

Dashti-Khavidaki, S., & Khalili, H. (2020). Considerations for Statin Therapy in Patients with COVID-19. Pharmacotherapy, 40(5), 484–486. https://doi.org/10.1002/phar.2397

De Melo, A. F., & Homem-De-Mello, M. (2020). High-dose intravenous vitamin C may help in cytokine storm in severe SARS-CoV-2 infection. Critical Care, 24(1), 1–2. https://doi.org/10.1186/s13054-020-03228-3

Flacco, M. E., Acuti Martellucci, C., Bravi, F., Parruti, G., Cappadona, R., Mascitelli, A., Manfredini, R., Mantovani, L. G., & Manzoli, L. (2020). Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: A meta-analysis. Heart, 106(19), 1519–1524. https://doi.org/10.1136/heartjnl-2020-317336

Frediansyah, A., Nainu, F., Dhama, K., Mudatsir, M., & Harapan, H. (2020). Remdesivir and its antiviral activity against COVID-19: A systematic review. Clinical Epidemiology and Global Health, July, 0–1. https://doi.org/10.1016/j.cegh.2020.07.011

Gautret, P., Lagier, J. C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Tissot Dupont, H., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, J. M., Brouqui, P., & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 56(1), 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949

Gendelman, O., Amital, H., Bragazzi, N. L., Watad, A., & Chodick, G. (2020). Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. Autoimmunity reviews, 102566.

Giaime, P., Guenoun, M., Pedinielli, N., Narbonne, H., Bergounioux, J. P., Solas, C., Guilhaumou, R., Sampol, J., Ollier, J., Sichez, H., Serveaux, M., Brunner, F., & Bataille, S. (2020). Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection. Nephrology Dialysis Transplantation, 35(8), 1346–1353. https://doi.org/10.1093/ndt/gfaa191

Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F.-X., Nicastri, E., Oda, R., Yo, K., Quiros-Roldan, E., Studemeister, A., Redinski, J., Ahmed, S., Bernett, J., Chelliah, D., … Flanigan, T. (2020). Compassionate Use of Remdesivir for Patients with Severe COVID-19. New England Journal of Medicine, 382(24), 2327–2336. https://doi.org/10.1056/nejmoa2007016

Horby, P., Lim, W.S., Emberson, J.R., Mafharn, M., Bell, J.L., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020). Dexamethasone in Hospitalized Patients with COVID-19 — Preliminary Report. The New England Journal of Medicine 1–11. https://doi.org/10.1056/NEJMoa2021436

Hui, D. S., I Azhar, E., Madani, T. A., Ntoumi, F., Kock, R., Dar, O., Ippolito, G., Mchugh, T. D., Memish, Z. A., Drosten, C., Zumla, A., & Petersen, E. (2020). The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases, 91(January), 264–266. https://doi.org/10.1016/j.ijid.2020.01.009

Jallouli, M., Galicier, L., Zahr, N., Aumaître, O., Francès, C., Le Guern, V., Lioté, F., Smail, A., Limal, N., Perard, L., Desmurs-Clavel, H., Le Thi Huong, D., Asli, B., Kahn, J. E., Pourrat, J., Sailler, L., Ackermann, F., Papo, T., Sacré, K., … Costedoat-Chalumeau, N. (2015). Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis and Rheumatology, 67(8), 2176–2184. https://doi.org/10.1002/art.39194

Junaid, K., Ejaz, H., Abdalla, A. E., Abosalif, K. O. A., Ullah, M. I., Yasmeen, H., Younas, S., Hamam, S. S. M., & Rehman, A. (2020). Effective immune functions of micronutrients against sars-CoV-2. Nutrients, 12(10), 1–14. https://doi.org/10.3390/nu12102992

Kelleni, M.T. (2020). Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management. Pharmacological Research, 157(2020), 104874. https://doi.org/10.1016.j.phrs.2020.104874

Kow, C.S. & Hasan, S.S. (2020). Meta-analysis of effect of statins in patients with COVID-19. The american journal of cardiology. (2020). 153–155. https://doi.org/10.1016/j.amjcard.2020.08.004

Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2015). Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 124(2), 188-195.

Lotfi, M., Hamblin, M. R., & Rezaei, N. (2020). COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clinica chimica acta, 508(January), 254–266.

Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., … Tan, W. (2020). Articles Genomic characterisation and epidemiology of 2019 novel coronavirus : implications for virus origins and receptor binding. The Lancet, 395(10224), 565–574. https://doi.org/10.1016/S0140-6736(20)30251-8

Mahmoud, D. B., Shitu, Z., & Mostafa, A. (2020). Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19? Journal of Genetic Engineering and Biotechnology, 18(1). https://doi.org/10.1186/s43141-020-00055-5

Molinaro, R., Pasto, A., Taraballi, F., Giordano, F., Azzi, J. A., Tasciotti, E., & Corbo, C. (2020). Biomimetic Nanoparticles Potentiate the Anti-Inflammatory Properties of Dexamethasone and Reduce the Cytokine Storm Syndrome: An Additional Weapon against COVID-19?. Nanomaterials, 10(11), 2301.

Pani, A., Lauriola, M., Romandini, A., & Scaglione, F. (2020). Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. International Journal of Antimicrobial Agents, 56(2), 106053. https://doi.org/10.1016/j.ijantimicag.2020.106053

Parra-Medina, R., Sarmiento-Monroy, J. C., Rojas-Villarraga, A., Garavito, E., Montealegre-Gómez, G., & Gómez-López, A. (2020). Colchicine as a possible therapeutic option in COVID-19 infection. Clinical Rheumatology, 39(8), 2485-2486.

Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V. (2019). Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discovery Today, 24(10), 2076–2085. https://doi.org/10.1016/j.drudis.2019.06.014

Ramamoorthy, S., & Cidlowski, J. A. (2016). Corticosteroids: mechanisms of action in health and disease. Rheumatic Disease Clinics, 42(1), 15-31.

Ramanathan, K., Antognini, D., Combes, A., Paden, M., Zakhary, B., Ogino, M., Maclaren, G., & Brodie, D. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(January), 497–506.

Reiner, Ž., Hatamipour, M., Banach, M., Pirro, M., Al-Rasadi, K., Jamialahmadi, T., Radenkovic, D., Montecucco, F., & Sahebkar, A. (2020). Statins and the COVID-19 main protease: In silico evidence on direct interaction. Archives of Medical Science, 16(2), 490–496. https://doi.org/10.5114/aoms.2020.94655

Retallack, H., Di Lullo, E., Arias, C., Knopp, K. A., Laurie, M. T., Sandoval-Espinosa, C., Leon, W. R. M., Krencik, R., Ullian, E. M., Spatazza, J., Pollen, A. A., Mandel-Brehm, C., Nowakowski, T. J., Kriegstein, A. R., & De Risi, J. L. (2016). Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proceedings of the National Academy of Sciences of the United States of America, 113(50), 14408–14413. https://doi.org/10.1073/pnas.1618029113

Reynolds, H. R., Adhikari, S., Pulgarin, C., Troxel, A. B., Iturrate, E., Johnson, S. B., Hausvater, A., Newman, J. D., Berger, J. S., Bangalore, S., Katz, S. D., Fishman, G. I., Kunichoff, D., Chen, Y., Ogedegbe, G., & Hochman, J. S. (2020). Renin–Angiotensin–Aldosterone System Inhibitors and Risk of COVID-19. New England Journal of Medicine, 382(25), 2441–2448. https://doi.org/10.1056/nejmoa2008975

Rizk, J. G., Kalantar-Zadeh, K., Mehra, M. R., Lavie, C. J., Rizk, Y., & Forthal, D. N. (2020). Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs, 80(13), 1267–1292. https://doi.org/10.1007/s40265-020-01367-z

Rossignol, J. F. (2016). Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. Journal of Infection and Public Health, 9(3), 227–230. https://doi.org/10.1016/j.jiph.2016.04.001

Sahakijpijarn, S., Moon, C., Koleng, J. J., Christensen, D. J., & Williams, R. O. (2020). Development of remdesivir as a dry powder for inhalation by thin film freezing. Pharmaceutics, 12(11), 1–27. https://doi.org/10.3390/pharmaceutics12111002

Schlesinger, N., Firestein, B. L., & Brunetti, L. (2020). Colchicine in COVID-19: an Old Drug, New Use. Current Pharmacology Reports, 6(4), 137–145. https://doi.org/10.1007/s40495-020-00225-6

Schögler, A., Kopf, B. S., Edwards, M. R., Johnston, S. L., Casaulta, C., Kieninger, E., Jung, A., Moeller, A., Geiser, T., Regamey, N., & Alves, M. P. (2015). Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. European Respiratory Journal, 45(2), 428–439. https://doi.org/10.1183/09031936.00102014

Schwartz, R. A., & Suskind, R. M. (2020). Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration. Dermatologic Therapy, 33(4), 2–4. https://doi.org/10.1111/dth.13785

Sharma, A., Tiwari, S., Deb, M. K., & Marty, J. L. (2020). Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. International Journal of Antimicrobial Agents, 56(2), 106054. https://doi.org/10.1016/j.ijantimicag.2020.106054

Sheikhzadeh, E., Eissa, S., Ismail, A., & Zourob, M. (2020). Diagnostic techniques for COVID-19 and new developments. Talanta, 220(July), 121392. https://doi.org/10.1016/j.talanta.2020.121392

Sirtori, C. R. (2014). The pharmacology of statins. Pharmacological Research, 88, 3–11. https://doi.org/10.1016/j.phrs.2014.03.002

Tai, T. T., Wu, T. J., Wu, H. D., Tsai, Y. C., Wang, H. T., Wang, A. M., ... & Chen, Y. C. (2021). A Strategy to Treat COVID‐19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study. Clinical and translational science, 14(1), 132-136.

Tang, Y., Liu, J., Zhang, D., Xu, Z., Ji, J., & Wen, C. (2020). Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Frontiers in Immunology, 11(July), 1–13. https://doi.org/10.3389/fimmu.2020.01708

Tardif, J. C., Bouabdallaoui, N., L’Allier, P. L., Gaudet, D., Shah, B., Pillinger, M. H., ... & COLCORONA Investigators. (2021). Efficacy of colchicine in non-hospitalized patients with COVID-19. Medrxiv.

Touret, F., Gilles, M., Barral, K., Nougairède, A., van Helden, J., Decroly, E., de Lamballerie, X., & Coutard, B. (2020). In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Scientific Reports, 10(1), 1–8. https://doi.org/10.1038/s41598-020-70143-6

Tripathy, S., Dassarma, B., Roy, S., Chabalala, H., & Matsabisa, M. G. (2020). A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. International journal of antimicrobial agents, 56(2), 106028.

Troeman, D. P. R., Postma, D. F., Van Werkhoven, C. H., & Oosterheert, J. J. (2013). The immunomodulatory effects of statins in community-acquired pneumonia: A systematic review. Journal of Infection, 67(2), 93–101. https://doi.org/10.1016/j.jinf.2013.04.015

Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30(3), 269–271. https://doi.org/10.1038/s41422-020-0282-0

Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., Larson, N., Strickley, R., Wells, J., Stuthman, K. S., Van Tongeren, S. A., Garza, N. L., Donnelly, G., Shurtleff, A. C., Retterer, C. J., … Bavari, S. (2016). Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature, 531(7594), 381–385. https://doi.org/10.1038/nature17180

White, N. J., Watson, J. A., Hoglund, R. M., Chan, X. H. S., Cheah, P. Y., & Tarning, J. (2020). COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. PLoS Medicine, 17(9), 1–24. https://doi.org/10.1371/journal.pmed.1003252

Williamson, B. N., Feldmann, F., Schwarz, B., Meade-White, K., Porter, D. P., Schulz, J., van Doremalen, N., Leighton, I., Yinda, C. K., Pérez-Pérez, L., Okumura, A., Lovaglio, J., Hanley, P. W., Saturday, G., Bosio, C. M., Anzick, S., Barbian, K., Cihlar, T., Martens, C., … de Wit, E. (2020). Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature, 585(7824), 273–276. https://doi.org/10.1038/s41586-020-2423-5

Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., ... & Wang, F. S. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine, 8(4), 420-422.

Yang, W., Dang, X., Wang, Q., Xu, M., Zhao, Q., Zhou, Y., Zhao, H., Wang, L., Xu, Y., Wang, J., Han, S., Wang, M., Pei, F., & Wan, Y. (2020). Rapid Detection of SARS-CoV-2 Using Reverse Transcription RT-LAMP Method. Health Evaluation and Promotion, 47(1), 248–250. https://doi.org/10.7143/jhep.47.248

Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., Zhan, S., Lu, R., Li, H., Tan, W., & Liu, D. (2020). In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases, 71(15), 732–739. https://doi.org/10.1093/cid/ciaa237

Ye, Z. W., Yuan, S., Yuen, K. S., Fung, S. Y., Chan, C. P., & Jin, D. Y. (2020). Zoonotic origins of human coronaviruses. International Journal of Biological Sciences, 16(10), 1686–1697. https://doi.org/10.7150/ijbs.45472

Zarogoulidis, P., Papanas, N., Kioumis, I., Chatzaki, E., Maltezos, E., & Zarogoulidis, K. (2012). Macrolides: From in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. European Journal of Clinical Pharmacology, 68(5), 479–503. https://doi.org/10.1007/s00228-011-1161-x

Zhou, Y., Wang, F., Tang, J., Nussinov, R., & Cheng, F. (2020). Artificial intelligence in COVID-19 drug repurposing. The Lancet Digital Health, 2(12), e667–e676. https://doi.org/10.1016/s2589-7500(20)30192-8

Zhu, Y., Li, J., & Pang, Z. (2020). Recent insights for the emerging COVID-19: Drug discovery, therapeutic options and vaccine development. Asian Journal of Pharmaceutical Sciences, xxxx, 1–21. https://doi.org/10.1016/j.ajps.2020.06.001



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.